Bellino Silvio, Bozzatello Paola, Rinaldi Camilla, Bogetto Filippo
Centre for Personality Disorders, Unit of Psychiatry 1, Department of Neurosciences, University of Turin, via Cherasco 11, 10126 Turin, Italy.
Depress Res Treat. 2011;2011:680194. doi: 10.1155/2011/680194. Epub 2011 Aug 4.
Antipsychotics are recommended for the treatment of impulsive dyscontrol and cognitive perceptual symptoms of borderline personality disorder (BPD). Three reports supported the efficacy of oral risperidone on BPD psychopathology. Paliperidone ER is the metabolite of risperidone with a similar mechanism of action, and its osmotic release reduces plasmatic fluctuations and antidopaminergic effects. The aim of this study is to evaluate efficacy and safety of paliperidone ER in BPD patients. 18 outpatients with a DSM-IV-TR diagnosis of BPD were treated for 12 weeks with paliperidone ER (3-6 mg/day). They were assessed at baseline, week 4, and week 12, using the CGI-Severity item, the BPRS, the HDRS, the HARS, the SOFAS, the BPD Severity Index (BPDSI), and the Barratt Impulsiveness Scale (BIS-11). Adverse events were evaluated with the DOTES. Paliperidone ER was shown to be effective and well tolerated in reducing severity of global symptomatology and specific BPD symptoms, such as impulsive dyscontrol, anger, and cognitive-perceptual disturbances. Results need to be replicated in controlled trials.
抗精神病药物被推荐用于治疗边缘型人格障碍（BPD）的冲动控制障碍和认知感知症状。三项报告支持口服利培酮对BPD精神病理学的疗效。帕利哌酮缓释片是利培酮的代谢产物，作用机制相似，其渗透释放可减少血浆波动和抗多巴胺能效应。本研究的目的是评估帕利哌酮缓释片在BPD患者中的疗效和安全性。18例符合DSM-IV-TR诊断标准的BPD门诊患者接受了12周的帕利哌酮缓释片治疗（3 - 6毫克/天）。在基线、第4周和第12周使用临床总体印象严重程度量表（CGI-Severity）、简明精神病评定量表（BPRS）、汉密尔顿抑郁量表（HDRS）、汉密尔顿焦虑量表（HARS）、社会功能大体评定量表（SOFAS）、BPD严重程度指数（BPDSI）和巴拉特冲动性量表（BIS-11）对他们进行评估。使用药物不良反应观察表（DOTES）评估不良事件。结果显示，帕利哌酮缓释片在减轻总体症状严重程度和特定的BPD症状（如冲动控制障碍、愤怒和认知感知障碍）方面有效且耐受性良好。结果需要在对照试验中进行重复验证。
